A Double Blind, Randomized, Multiple Dose, Placebo And Active Controlled 4-Way Crossover Study To Investigate The Effects Of Inhaled PF-00610355 On QT/QTC Interval In Healthy Subjects.

Trial Profile

A Double Blind, Randomized, Multiple Dose, Placebo And Active Controlled 4-Way Crossover Study To Investigate The Effects Of Inhaled PF-00610355 On QT/QTC Interval In Healthy Subjects.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2011

At a glance

  • Drugs Moxifloxacin; PF 610355
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Asthma; Chronic obstructive pulmonary disease; Community-acquired pneumonia; Intra-abdominal infections; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Jan 2011 Actual initiation date changed from 1 May 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Additional trial location [Belgium] identified as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Actual initiation date (May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top